SEARCH

Current Edition

allogeneic cell therapies

Gilead’s Kite bets on early-stage biotech to advance allogeneic cell therapies

The deal with Appia is yet another step in Gilead’s efforts to become an oncology powerhouse — a strategy the company has made clear through …

Continue Reading →